BioSpace

AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations

AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising questions about its commercial prospects.

By BioSpace

1 min read
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights